Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy.
Br J Haematol. 2024 Jul;205(1):17-19. doi: 10.1111/bjh.19503. Epub 2024 May 30.
The prognosis of r/r DLBCL has changed substantially over the past decade due to the introduction of T-cell-activating therapies. Besides generating a new curative perspective for a proportion of r/r DLBCL, chimeric antigen receptor T-cell therapy and bispecific antibodies are generating new unmet needs. The report by Grigg and colleagues now shows that glofitamab-refractory, CD20-negative patients represent a new unmet medical need requiring therapeutic targets other than CD20 and novel therapies to reduce the risk of CD20 loss. Commentary on: Grigg et al. Relapse after glofitamab has a poor prognosis, and rates of CD20 loss are high. Br J Haematol 2024;205:122-126.
由于 T 细胞激活疗法的引入，r/r DLBCL 的预后在过去十年中发生了重大变化。嵌合抗原受体 T 细胞疗法和双特异性抗体除了为一部分 r/r DLBCL 产生新的治愈前景外，还产生了新的未满足的需求。Grigg 及其同事的报告现在表明，glofitamab 耐药、CD20 阴性患者代表了一种新的未满足的医疗需求，需要除 CD20 以外的治疗靶点和新的疗法来降低 CD20 丢失的风险。述评：Grigg 等人。glofitamab 治疗后复发预后不良，且 CD20 丢失率高。英国血液学杂志 2024；205：122-126。
